Home > Result Summaries: Compounds > naratriptan > Result Summary for S2W40012

Result Summary for S2W40012

Result Summary

Protocol ID:	S2W40012
Clinical Study ID:	S2W40012
Official Title:	A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily asprophylactic treatment for menstrually-associated migraine.
Phase:	Phase 4
Study Indications or Diseases:	Migraine Disorders
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Nett R, Mannix L, Landy S et al. Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg Twice Daily as Prophylactic Treatment for Menstrually-Associated Migraine. Platform Presentation at the 55th Annual Meeting of the American Academy of Neurology, Honolulu, HA. March 29-April 5th, 2003. [S15.006]. Mannix LK et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007;47:1037-1049. Abstract: Naratriptan for intermittent prophylaxis for menstrually-associated migraine: an analysis of migraine-free days. Diamond, M., Aurora, S., Ames, M., and Shackelford, S. 45th Annual Scientific Meeting of the American Headache Society (AHS) 6/19/2003 Chicago, IL; USA